Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Purpose:
The overall objective of this study is to learn more about the disease chronic pancreatitis and thus contribute to better treatments. The investigators will gain this by studying the effects of vitamin D in the body immune system and bones. The investigators will also study the uptake of vitamin D through the intestine compared with the amount of vitamin D obtained through exposure to UVB rays.
The investigators have set a series of questions which the investigators want to answer with this experiment:
Do patients with chronic pancreatitis have reduced absorption of vitamin D from the gut?
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo | Placebo Comparator |
| |
| Vitamin D administered orally | Active Comparator |
| |
| Vitamin D administered via UVB | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Calcium, Dietary | Drug | 400 mg calcium two times daily. From week 0 to 10 and week 14 to 52. |
|
| Measure | Description | Time Frame |
|---|---|---|
| 25-hydroxyvitamin D | Week 0, 2, 6, 10, 14, 20, 30, 40, 52 |
| Measure | Description | Time Frame |
|---|---|---|
| T-lymphocytes subsets. | Subsets of T-lymphocytes including regulatory T-lymphocytes (Tregs) and CD4+ and CD8+ lymphocytes. | Week 0, 10 |
| Ionized calcium | week 0, 2, 6, 10, 14, 20, 30, 40, 52 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jens-Erik B Jensen, Ph.d. | Dept. of osteoporosis, Hvidovre Hospital | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hvidovre Hospital | Hvidovre | 2650 | Denmark |
Not provided
| ID | Term |
|---|---|
| D050500 | Pancreatitis, Chronic |
| D008286 | Malabsorption Syndromes |
| ID | Term |
|---|---|
| D010195 | Pancreatitis |
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
| ID | Term |
|---|---|
| D002136 | Calcium, Dietary |
| D002762 | Cholecalciferol |
| ID | Term |
|---|---|
| D017610 | Calcium Compounds |
| D007287 | Inorganic Chemicals |
| D002782 | Cholestenes |
| D002776 | Cholestanes |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Cholecalciferol | Drug | 38 micrograms daily. Week 0-10. |
|
|
| UVB | Radiation | Ultraviolet radiation type B administered in a tanning bed. One time weekly. |
|
|
| UV-filtered light. | Radiation | Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly. |
|
|
| Cholecalciferol | Drug | 38 micrograms daily. From week 14 to 52. |
|
|
| Parathyroid hormone | To evaluate bone-metabolism. | Week 0, 2, 6, 10, 14, 20, 30, 40, 52 |
| QoL score | Evaluation of self-reported health using two questionnaires: QLQ-C30 QLQ-Pan(30) | Week 0, 10 |
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007410 | Intestinal Diseases |
| D005767 | Gastrointestinal Diseases |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D013256 |
| Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
| D013261 | Sterols |
| D014807 | Vitamin D |
| D012632 | Secosteroids |
| D008563 | Membrane Lipids |
| D008055 | Lipids |